5 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Harnessing Targeted Nanotheranostics to Reprogram Activated Leukocytes in Inflammatory Bowel Disease (LeukoTheranostics)
Date du début: 1 nov. 2015, Date de fin: 31 oct. 2020,
"Inflammatory bowel diseases (IBD) is a group of chronic inflammatory conditions of the gastrointestinal tract, including Crohn’s disease (CD) and Ulcerative Colitis (UC) that can impact both the large and small bowel. IBD affects approximately 3.7 million Europeans and its peak onset is in persons of 15 to 30 years of age. IBD imposes a significant burden on Europe with over €3B in annual health ...
Voir le projet
2
Participants partenaires
TERMINÉ
Models of Child Health Appraised (MOCHA)
Date du début: 1 juin 2015, Date de fin: 30 nov. 2018,
Children’s health affects the future of Europe – children are citizens, future workers, parents and carers. Children are dependent on society to provide effective health services (UN Convention on the Rights of the Child). Models of child primary health care vary widely across Europe based on two broad alternatives (primary care paediatricians or generic family doctors), and a variety of models of ...
Voir le projet
20
Participants partenaires
TERMINÉ
New approach to treatment of the blinding disease Retinopathy of Prematurity (ROP) (PREVENTROP)
Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,
"The overall objective is to develop a novel preventative intervention for the blinding disease retinopathy of prematurity (ROP) and other complications of prematurity. The PREVENTROP consortium proposes to conduct preclinical studies (pharmacological, pharmacodynamics, pharmacokinetics and toxicological) in models and/or clinical studies (including phase III clinical trial) of an EU designated o ...
Voir le projet
10
Participants partenaires
TERMINÉ
THALAssaemia MOdular Stratification System for personalized therapy of beta-thalassemia (THALAMOSS)
Date du début: 1 nov. 2012, Date de fin: 31 oct. 2016,
...Philipsen (Erasmus Universitair Medisch Centrum Rotterdam, The Netherlands), E.Katsantoni (Biomedical Research Foundation, Academy of Athens, Greece), S.Rivella (Cornell University, NY, USA - The Children's Hospital of Philadelphia, Philadelphia, USA), P.Holub (Masaryk University, Czech Republic), P. Moi (Cagliari University, Italy), S. Menzel and SL.Thein (King’s College Hospital, UK), E.Voska ...
Voir le projet
14
Participants partenaires
TERMINÉ
A phase I/IIa clinical trial in Duchenne muscular dystrophy using systemically delivered morpholino antisense oligomer to skip exon 53 (SKIP-NMD)
Date du début: 1 nov. 2012, Date de fin: 30 avr. 2016,
Duchenne muscular dystrophy (DMD) is a progressive, lethal muscle degenerative condition arising from the absence of dystrophin in skeletal and cardiac muscles. 65% of DMD boys have out-of-frame deletions. Modulation of pre-mRNA splicing by exon skipping is the most promising molecular intervention in DMD. 2 Phase Ib and 2 Phase IIa clinical trials (MDEX Consortium in collaboration with Sarepta Th ...
Voir le projet